Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation

Trial Identifier: D8224C00001
Sponsor: AstraZeneca
Start Date: June 2021
Primary Completion Date: September 2024
Study Completion Date: September 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan Aichi, Japan, D8224C00001
Japan Aichi, Japan
Japan Akita, Japan
Japan Aomori, Japan, D8224C00001
Japan Chiba, Japan
Japan Chiba, Japan, D8224C00001
Japan Fukui, Japan
Japan Fukuoka, Japan, D8224C00001
Japan Fukuoka, Japan
Japan Gifu, Japan
Japan Gunma, Japan, D8224C00001
Japan Gunma, Japan
Japan Hiroshima, Japan, D8224C00001
Japan Hiroshima, Japan
Japan Hokkaido, Japan
Japan Hokkaido, Japan, D8224C00001
Japan Hyogo, Japan
Japan Hyogo, Japan, D8224C00001
Japan Ibaraki, Japan
Japan Ibaraki, Japan, D8224C00001
Japan Ishikawa, Japan
Japan Iwate, Japan
Japan Kagoshima, Japan, D8224C00001
Japan Kagoshima, Japan
Japan Kanagawa, Japan, D8224C00001
Japan Kanagawa, Japan
Japan Kochi, Japan
Japan Kumamoto, Japan
Japan Kyoto, Japan
Japan Kyoto, Japan, D8224C00001
Japan Mie, Japan
Japan Miyagi, Japan, D8224C00001
Japan Miyagi, Japan
Japan Miyazaki, Japan
Japan Nagano, Japan
Japan Nagasaki, Japan
Japan Nagasaki, Japan, D8224C00001
Japan Nara, Japan
Japan Niigata, Japan
Japan Oita, Japan
Japan Okayama, Japan
Japan Okinawa, Japan
Japan Osaka, Japan
Japan Osaka, Japan, D8224C00001
Japan Saitama, Japan
Japan Saitama, Japan, D8224C00001
Japan Shiga, Japan, D8224C00001
Japan Shiga, Japan
Japan Shimane, Japan
Japan Shizuoka, Japan, D8224C00001
Japan Shizuoka, Japan
Japan Tokyo, Japan
Japan Tokyo, Japan, D8224C00001
Japan Tottori, Japan
Japan Toyama, Japan
Japan Wakayama, Japan, D8224C00001
Japan Wakayama, Japan
Japan Yamagata, Japan
Japan Yamaguchi, Japan